Marchetti C, Rosati A, Scaletta G, et al. - Researchers performed a case-control study to determine the role of secondary cytoreductive surgery (SCS) in platinum-sensitive recurrent ovarian cancer (PSROC) patients with BRCA1/2 mutation (BRCAmut) who received platinum-based chemotherapy followed by olaparib maintenance. From their Gynecologic Oncology Unit, they identified 46 patients for this study; they matched 23 (50%) BRCAmut women undergoing SCS followed by platinum-based chemotherapy and olaparib maintenance with 23 (50%) BRCAmut women who only received medical treatment. They observed that time to first subsequent therapy and postrecurrence survival increases in PSROC patients with BRCAmut candidate for olaparib maintenance after platinum-based chemotherapy in correlation to receipt of SCS. They recommend individualizing an indication of SCS in the era of personalized medicine.